KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Assets (2016 - 2025)

Inovio Pharmaceuticals' Current Assets history spans 15 years, with the latest figure at $97.8 million for Q4 2024.

  • For Q4 2024, Current Assets fell 36.11% year-over-year to $97.8 million; the TTM value through Dec 2024 reached $97.8 million, down 36.11%, while the annual FY2024 figure was $97.8 million, 36.11% down from the prior year.
  • Current Assets for Q4 2024 was $97.8 million at Inovio Pharmaceuticals, down from $117.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $588.4 million in Q1 2021 and bottomed at $97.8 million in Q4 2024.
  • The 5-year median for Current Assets is $377.1 million (2020), against an average of $347.3 million.
  • The largest annual shift saw Current Assets skyrocketed 400.18% in 2020 before it plummeted 51.43% in 2023.
  • A 5-year view of Current Assets shows it stood at $471.2 million in 2020, then dropped by 4.82% to $448.4 million in 2021, then dropped by 29.7% to $315.2 million in 2022, then tumbled by 51.43% to $153.1 million in 2023, then tumbled by 36.11% to $97.8 million in 2024.
  • Per Business Quant, the three most recent readings for INO's Current Assets are $97.8 million (Q4 2024), $117.6 million (Q2 2024), and $153.1 million (Q4 2023).